Clinical Trials in Miami

Showing 6041-6060 of 11,431 trials

Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune Systems

NCT00006066

The purpose of this study is to determine the safety of a drug called interleukin-2 (IL-2) given with anti-HIV therapy in children with HIV infection. This study will also determine the best dose of IL-2 to give children. IL-2 is an important substance produced by the body's white blood cells that helps the body fight infection. People with HIV infection do not produce enough IL-2. It is hoped that IL-2 treatment will help boost the immune system in people with HIV infection. It has not been studied very much in children and doctors need to know what doses are safe to give.

HIV Infections

National Institute of Allergy and Infectious Diseases (NIAID)92 participants

Long Beach, California, United States • Los Angeles, California, United States • San Diego, California, United States +11 more locations

COMPLETEDPhase 2< 1 mile

Comparison of Two Methods in the Treatment of Cytomegalovirus of the Eyes in Patients With AIDS

NCT00001061

To evaluate the effect of MSL 109, human monoclonal anti-cytomegalovirus (CMV) antibody, on time to progression of CMV retinitis. To determine the safety and pharmacokinetic profile of MS 109. To evaluate the relationship between pharmacokinetic measurements of MSL 109 and efficacy and virologic markers. Therapeutic agents currently available for CMV retinitis are limited by their inherent toxicities and short half-lives which require frequent intravenous dosing. Alternatively, MSL 109 has demonstrated safety and effectiveness in neutralizing CMV isolates at concentrations easily maintained in AIDS patients.

Cytomegalovirus RetinitisHIV Infections

National Institute of Allergy and Infectious Diseases (NIAID)167 participants

Birmingham, Alabama, United States • Los Angeles, California, United States • San Jose, California, United States +17 more locations

Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune Systems

Comparison of Two Methods in the Treatment of Cytomegalovirus of the Eyes in Patients With AIDS

Find Trials by Condition in Miami

Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV

Combination Treatment With and Without Protease Inhibitors for Women Who Begin Therapy for HIV Infection During Pregnancy

Adding New Drugs for HIV Infected Patients Failing Current Therapy

A Study of HIV-Disease Development in Aging

Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV

A Study of the Safety and Effectiveness of Treating Advanced AIDS Patients Between Ages 4 and 22 With 7 Drugs, Some at Higher Than Usual Doses

A Study of DAPD Alone Versus DAPD Plus MMF for Treatment of HIV Infection

The Safety and Effectiveness of Clarithromycin and Rifabutin Used Alone or in Combination to Prevent Mycobacterium Avium Complex (MAC) or Disseminated MAC Disease in HIV-Infected Patients

Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401)

Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis

Safety and Effectiveness of Lopinavir/Ritonavir in HIV Infected Infants

Safety of Saquinavir and High Doses of Lopinavir/Ritonavir in Children With HIV

A Study of Megestrol Acetate Alone or in Combination With Testosterone Enanthate Drug in the Treatment of HIV-Associated Weight Loss

An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age

Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative Volunteers

Testosterone for HIV-Positive Men With Reduced Serum Testosterone Levels and Abdominal Fat

The Effectiveness of Nelfinavir and Efavirenz, Used Alone or Together, Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs

A Study to Evaluate the Ability of TNFR:Fc to Decrease the Amount of IL-6 (Interleukin-6) and TNF-alpha (Tumor Necrosis Factor) in HIV-Infected Patients